dc.contributor.author |
Samad, Noreen |
|
dc.contributor.author |
Yasmin, Farzana |
|
dc.contributor.author |
Haleem, Darakhshan Jabeen |
|
dc.date.accessioned |
2022-10-07T10:22:44Z |
|
dc.date.available |
2022-10-07T10:22:44Z |
|
dc.date.issued |
2016-11-16 |
|
dc.identifier.issn |
1011-601X |
|
dc.identifier.uri |
http://142.54.178.187:9060/xmlui/handle/123456789/12785 |
|
dc.description.abstract |
Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive
dyskinesia (TD). 0.2 mg/kg/rat dosage of haloperidol provided orally to rats for 2 weeks enhanced vacuous chewing movements that escalated when the process proceeded for 5 weeks. Following 2 weeks co-injection 5 mg/kg dosage of IMI was diminished haloperidol-instigated VCMs and fully averted following five weeks. The potency of 8-OH-DPATinstigated locomotor activity exhibited higher in saline+haloperidol treated rats while not observed in IMI+ haloperidol treated rats. 8-OH-DPAT-instigated low 5-hydroxytryptamine (5-HT; serotonin) metabolism was higher in saline+ haloperidol treated rats when compare to IMI+ haloperidol treated rats in both regions of brain (striatum and midbrain). It is recommended that IMI possibly competent in averting TD, in cases receiving treatment to antipsychotics. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi |
en_US |
dc.subject |
Tardive dyskinesia |
en_US |
dc.subject |
Imipramine |
en_US |
dc.subject |
Haloperidol |
en_US |
dc.subject |
Serotonin-1A receptor |
en_US |
dc.title |
Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions |
en_US |
dc.type |
Article |
en_US |